ArticleFrontiers in immunology2025
Prognostic differential subpopulation classification and immunotherapy response prediction in pancreatic cancer patients based on the gene features of necrotizing apoptosis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aims to explore the prognostic significance of necroptosis-related genes in pancreatic cancer. Methods: First, clustering analysis was performed on 15 necroptosis-related genes, which led to the identification of two distinct NRG subtypes. Differential expression analysis revealed 495 genes associated with prognosis, which were subsequently used for a second round of clustering. Next, a prognostic model was constructed using seven key genes, and patients were classified into high-risk and low-risk groups. External cohort data were used to validate the prognostic model. Spearman correlation analysis was conducted to examine the relationship between the most important biomarker, CHST11, and the 15 NRG genes. Additionally, three single-cell datasets, along with Mendelian randomization and spatial transcriptomics analyses, were utilized to further investigate the associations between CHST11, immune therapy, immune cells, and malignant epithelial cells. Results: NRGcluster A and geneCluster B largely overlapped, with most patients classified into the low-risk group. Among the 15 NRG genes, 11 exhibited significant expression differences between the high-risk and low-risk groups. CHST11 was identified as the most important prognostic biomarker and showed significant correlations with 13 NRG genes. Further analysis revealed potential mechanisms of action for CHST11. Discussion: This study, through multi-omics data, reveals that CHST11 may be associated with necroptosis and is closely related to the malignant prognosis of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.